The Relationship of Visfatin Levels with Insulin Resistance and Left Ventricular Hypertrophy in Peritoneal Dialysis Patients

REFERENCES

• Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106:473–481.
   PubMed Web of Science ®Google Scholar
• Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115:911–919.
   PubMed Web of Science ®Google Scholar
• Fukuhara A, Matsuda M, Nishizawa M, . Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426–430.
   PubMed Web of Science ®Google Scholar
• Berndt J, Kloting N, Kralisch S, . Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes. 2005;54:2911–2916.
   PubMed Web of Science ®Google Scholar
• Ingelsson E, Larson MG, Fox CS, . Clinical correlates of circulating visfatin levels in a community based sample. Diabetes Care. 2007;30:1278–1280.
   PubMedGoogle Scholar
• Filippatos TD, Derdemezis CS, Kiortisis DN, . Increased plasma levels of visfatin/pre-B cell colony enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest. 2007;30(4):323–326.
   Google Scholar
• Kenji O, Kiminori Y, Nozomu K, . Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol (Oxf). 2007;67(5):796–800.
   Google Scholar
• Pagano C, Pilon C, Olivieri M, . Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab. 2006;91(8):3165–3170.
   PubMed Web of Science ®Google Scholar
• Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metab Clin Exp. 2007;56:451–458.
   PubMed Web of Science ®Google Scholar
• Adya R, Tan BK, Punn A, Chen J, Randeva HS. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: Novel insights into visfatin-induced angiogenesis. Cardiovasc Res. 2008;78:356–365.
   PubMed Web of Science ®Google Scholar
• Axelsson J, Witasp A, Carrero JJ, . Circulating levels of visfatin/ pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis. 2007;49:237–244.
   PubMed Web of Science ®Google Scholar
• Wang P, Xu TY, Guan YF, Su DF, Fan GR, Miao CY. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: Role of nicotinamide mononucleotide. Cardiovasc Res. 2009;81:370–380.
   PubMed Web of Science ®Google Scholar
• Yamawaki H, Hara N, Okada M, Hara Y. Visfatin causes endothelium dependent relaxation in isolated blood vessels. Biochem Biophys Res Commun. 2009;383:503–508.
   PubMed Web of Science ®Google Scholar
• Twardowski ZJ, Nolph KD, Khanna R. Peritoneal equilibration test. Perit Dial Bull. 1987;7:138–147.
   Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419.
   PubMed Web of Science ®Google Scholar
• Sahn DJ, De Maria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation. 1978;58:1072–1083.
   PubMed Web of Science ®Google Scholar
• Devereux RB, Alonso DR, Lutas EM, . Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. J Am Coll Cardiol. 1986;57:450–458.
   Web of Science ®Google Scholar
• Witowski J, Korybalska K, Wisniewska J. Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol. 2000;11:729–739.
   PubMed Web of Science ®Google Scholar
• Davies SJ, Phillips L, Naish PF. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol. 2001;12:1046–1051.
   PubMed Web of Science ®Google Scholar
• Holmes C, Shockley T. Strategies to reduce glucose exposure in peritoneal dialysis patients. Perit Dial Int. 2000;20:S37–S41.
   Google Scholar
• Mistry CD, Gokal R, Peers E, MIDAS study group. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solution in CAPD. Kidney Int. 1994;46:496–503.
   PubMed Web of Science ®Google Scholar
• Heimburger O, Waniewski J, Werynski A, . A quantitative description of solute and fluid transport during peritoneal dialysis. Kidney Int. 1992;41:1320–1332.
   PubMed Web of Science ®Google Scholar
• Desanto NG, Capodicasa G, Senatore R, . Glucose utilization from dialysate in patients on CAPD. Int J Artif Organs. 1979;2:119–125.
   PubMed Web of Science ®Google Scholar
• Grodstein GP, Blumenkrantz MJ, Kopple JD, . Glucose absorption during continuous ambulatory peritoneal dialysis. Kidney Int. 1981;19:564–567.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J. Insulin resistance in uremia. J Clin Invest. 1981;67:563–568.
   PubMed Web of Science ®Google Scholar
• Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111:1448–1454.
   PubMed Web of Science ®Google Scholar
• El-Atat FA, Stas SN, McFarlane SI, Sowers JR. The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol. 2004;15:2816–2827.
   PubMed Web of Science ®Google Scholar
• Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115:1111–1119.
   PubMed Web of Science ®Google Scholar
• Fortes PC, Mendes JG, Riella MC, Pecoits-Filho R. Carbohydrate metabolism disturbances in non-diabetic patients on peritoneal dialysis [Abstract]. Perit Dial Int. 2006;26(Suppl. 2):S26.
   Google Scholar
• Juge-Aubry CE, Henrichot E, Meier CA. Adipose tissue: A regulator of inflammation. Best Pract Res Clin Endocrinol Metab. 2005;19(4):547–566.
   PubMedGoogle Scholar
• Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab. 2006;91(4):1578–1581.
   PubMed Web of Science ®Google Scholar
• Chen MP, Chung FM, Chang DM, . Elevated plasma level of visfatin/pre-B cell colony enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2006;91(1):295–299.
   PubMed Web of Science ®Google Scholar
• Krzyzanowska K, Krugluger W, Mittermayer F, Rahma R, Haider D, Shnawa N. Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci. 2006;1: 605–609.
   Google Scholar
• D´ıez JJ, Iglesias P, Fern´andez-Reyes MJ, . Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol (Oxf). 2005;62:242–249.
   PubMed Web of Science ®Google Scholar
• Stenvinkel P, Ketteler M, Johnson RJ, . IL-10, IL-6, and TNF-alpha: Central factors in the altered cytokine network of uremia—the good, the bad, and the ugly. Kidney Int. 2005;67:216–233.
   Google Scholar
• Erten Y, Ebinç FA, Ebinç H, . The relationship of visfatin levels to inflammatory cytokines and left ventricular hypertrophy in hemodialysis and continuous ambulatory peritoneal dialysis patients. Ren Fail. 2008;30:617–623.
   PubMed Web of Science ®Google Scholar
• Cottone S, Nardi E, Mule G, . Association between biomarkers of inflammation and left ventricular hypertrophy in moderate chronic kidney disease. Clin Nephrol. 2007;67(4):209–216.
   Google Scholar
• Pannier B, Guerin AP, Marchais SJ, Metivier F, Safar ME, London GM. Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in end-stage renal disease. Kidney Int. 2000;57(3):1091–1099.
   PubMed Web of Science ®Google Scholar
• London GM, Blacher J, Pannier B, Guérin AP, Marchais SJ, Safar ME. Arterial wave reflections and survival in end-stage renal failure. Hypertension. 2001;38:434–438.
   PubMed Web of Science ®Google Scholar
• Rongvaux A, Shea RJ, Mulks MH, . Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol. 2002;32:3225–3234.
   PubMed Web of Science ®Google Scholar